Table 3 Cancer diagnosis/type, chemotherapy agent class and radiation therapy (Medical Record Review cohort only)
From: Cardiotoxicity after cancer treatment: a process map of the patient treatment journey
| N = 46 | Mean (range) | n (%) |
|---|---|---|
| Cancer diagnosis | ||
| Age at first cancer diagnosis (years) | 53.6 (6.3–89.3) | 46 (100) |
| Bile duct | 1 (2) | |
| Breast | 14 (30) | |
| Colon | 1 (2) | |
| Hodgkin’s lymphoma | 1 (2) | |
| Leukaemia | 3 (7) | |
| Lung | 1 (2) | |
| Lymphoma | 7 (15) | |
| Non-Hodgkin’s | 11 (24) | |
| Oesophagus | 1 (2) | |
| Osteosarcoma | 4 (9) | |
| Prostate | 1 (2) | |
| Missing | 1 (2) | |
| Agent Class | ||
| Chemotherapy cyclesb,c | 5.2 (1–18) | |
| Alkylating | Mean dose (mg) | |
| Carboplatin | 520.0 | 2 (4) |
| Chlorambucila | 1 (2) | |
| Cisplatin | 113.3 | 5 (11) |
| Cyclophosphamide | 1148.1 | 21 (48) |
| Anthracyclines | ||
| Doxorubicin | 462.1 | 18 (39) |
| Epirubicin | 164.0 | 2 (4) |
| Anthracycline combination | ||
| ABVDa | 1 (2) | |
| Antibiotic cytotoxics | ||
| Bleomycin | 20.0 | 1 (2) |
| Antimetabolites | ||
| ATRA Azacitidine therapy | 100.0 | 1 (2) |
| Adjuvant CTx with carboplatin/gemcitabinea | 1 (2) | |
| Fluorouracil | 980.0 | 3 (7) |
| Methotrexate | 63.0 | 5 (11) |
| Fludarabine phosphatea | 1 (2) | |
| Mitotic Inhibitors | ||
| Amsacrine | 140.0 | 1 (2) |
| Docetaxel | 145.7 | 4 (9) |
| Etoposide | 200.0 | 1 (2) |
| Paclitaxel | 429.0 | 3 (7) |
| Vincristinea | 12 (26) | |
| Monoclonal Antibodies | ||
| Rituximab | 655.0 | 11 (24) |
| Trastuzumab | 378.1 | 7 (15) |
| Radiation therapy | 28 (61) | |